Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration.

OBJECTIVE Intervertebral disc degeneration is linked to loss of extracellular matrix (ECM), particularly the early loss of aggrecan. A group of metalloproteinases called aggrecanases are important mediators of aggrecan turnover. The present study was undertaken to investigate the expression of the recognized aggrecanases and their inhibitor, tissue inhibitor of metalloproteinases 3 (TIMP-3), in human intervertebral disc tissue. METHODS Twenty-four nondegenerated and 30 degenerated disc samples were analyzed for absolute messenger RNA (mRNA) copy number of ADAMTS 1, 4, 5, 8, 9, and 15 and TIMP-3 by real-time reverse transcription-polymerase chain reaction. Thirty-six formalin-fixed embedded intervertebral disc samples of varying grades of degeneration were used for immunohistochemical analyses. In addition, samples from 8 subjects were analyzed for the presence of matrix metalloproteinase (MMP)- and aggrecanase-generated aggrecan products. RESULTS Messenger RNA for all the aggrecanases other than ADAMTS-8 was identified in intervertebral disc tissue, as was mRNA for TIMP-3. Levels of mRNA expression of ADAMTS 1, 4, 5, and 15 were significantly increased in degenerated tissue compared with nondegenerated tissue. All these aggrecanases and TIMP-3 were also detected immunohistochemically in disc tissue, and numbers of nucleus pulposus cells staining positive for ADAMTS 4, 5, 9, and 15 were significantly increased in degenerated tissue compared with nondegenerated tissue. Aggrecan breakdown products generated by MMP and aggrecanase activities were also detected in intervertebral disc tissue. CONCLUSION The aggrecanases ADAMTS 1, 4, 5, 9, and 15 may contribute to the changes occurring in the ECM during intervertebral disc degeneration. Targeting these enzymes may be a possible future therapeutic strategy for the prevention of intervertebral disc degeneration and its associated morbidity.

[1]  A. Freemont,et al.  Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc. , 2008, Rheumatology.

[2]  H. An,et al.  Aggrecanases and Aggrecanase-generated Fragments in the Human Intervertebral Disc at Early and Advanced Stages of Disc Degeneration , 2007, Spine.

[3]  S. Schelling,et al.  Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis. , 2007, Arthritis and rheumatism.

[4]  A. Freemont,et al.  Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1β and TNFα expression profile , 2007, Arthritis research & therapy.

[5]  A. Freemont,et al.  Accelerated cellular senescence in degenerate intervertebral discs: a possible role in the pathogenesis of intervertebral disc degeneration , 2007, Arthritis research & therapy.

[6]  D. Griggs,et al.  Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. , 2007, Arthritis and rheumatism.

[7]  A. Freemont,et al.  A preliminary in vitro study into the use of IL‐1Ra gene therapy for the inhibition of intervertebral disc degeneration , 2006, International journal of experimental pathology.

[8]  S. Kumar,et al.  Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. , 2006, Osteoarthritis and cartilage.

[9]  栄重 波多野.  Expression of ADAMTS-4 (aggrecanase-1) and possible involvement in regression of lumbar disc herniation , 2006 .

[10]  K. Nishida,et al.  ADAMTS-9 is synergistically induced by interleukin-1β and tumor necrosis factor α in OUMS-27 chondrosarcoma cells and in human chondrocytes , 2005 .

[11]  A. Fourie,et al.  ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro , 2005, Nature.

[12]  D. Edwards,et al.  The ADAMTS metalloproteinases. , 2005, The Biochemical journal.

[13]  P. Roughley,et al.  Distinction between the extracellular matrix of the nucleus pulposus and hyaline cartilage: a requisite for tissue engineering of intervertebral disc. , 2004, European cells & materials.

[14]  A. Freemont,et al.  Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc , 2004, The Journal of pathology.

[15]  A. Dorner,et al.  ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. , 2004, Matrix biology : journal of the International Society for Matrix Biology.

[16]  C. Speed.  Low back pain , 2004, BMJ : British Medical Journal.

[17]  R. Leduc,et al.  Characterization of ADAMTS-9 and ADAMTS-20 as a Distinct ADAMTS Subfamily Related to Caenorhabditis elegans GON-1* , 2003, The Journal of Biological Chemistry.

[18]  M. Kashiwagi,et al.  Aggrecanases and cartilage matrix degradation , 2003, Arthritis research & therapy.

[19]  P. Roughley,et al.  The role of proteoglycans in aging, degeneration and repair of the intervertebral disc. , 2002, Biochemical Society transactions.

[20]  T. Burn,et al.  Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[21]  N. Boos,et al.  2002 SSE Award Competition in Basic Science: Expression of major matrix metalloproteinases is associated with intervertebral disc degradation and resorption , 2002, European Spine Journal.

[22]  M. Tortorella,et al.  Inhibition of ADAM-TS4 and ADAM-TS5 Prevents Aggrecan Degradation in Osteoarthritic Cartilage* , 2002, The Journal of Biological Chemistry.

[23]  M. Iruela-Arispe,et al.  ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. , 2002, Biochemical and biophysical research communications.

[24]  A. Freemont,et al.  Expression of chondrocyte markers by cells of normal and degenerate intervertebral discs , 2002, Molecular pathology : MP.

[25]  Víctor Quesada,et al.  Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. , 2002, Gene.

[26]  L. Sandell,et al.  Expression of type II procollagens during development of the human intervertebral disc. , 2001, Biochemical Society transactions.

[27]  Neil D. Rawlings,et al.  MEROPS: the protease database , 2002, Nucleic Acids Res..

[28]  M Kashiwagi,et al.  TIMP-3 Is a Potent Inhibitor of Aggrecanase 1 (ADAM-TS4) and Aggrecanase 2 (ADAM-TS5)* , 2001, The Journal of Biological Chemistry.

[29]  B. Caterson,et al.  Matrix Metalloproteinases And Aggrecanase: Their Role in Disorders of the Human Intervertebral Disc , 2000, Spine.

[30]  R. Maciewicz,et al.  Mutations in the Interglobular Domain of Aggrecan Alter Matrix Metalloproteinase and Aggrecanase Cleavage Patterns , 2000, The Journal of Biological Chemistry.

[31]  K. Brew,et al.  TIMP-3 Binds to Sulfated Glycosaminoglycans of the Extracellular Matrix* , 2000, The Journal of Biological Chemistry.

[32]  P. Slocombe,et al.  The in vitro activity of ADAM‐10 is inhibited by TIMP‐1 and TIMP‐3 , 2000, FEBS letters.

[33]  J. Urban,et al.  Regulation of Intracellular pH by Bovine Intervertebral Disc Cells , 2000, Cellular Physiology and Biochemistry.

[34]  K. Brew,et al.  Tissue inhibitors of metalloproteinases: evolution, structure and function. , 2000, Biochimica et biophysica acta.

[35]  E Viikari-Juntura,et al.  Low back pain in relation to lumbar disc degeneration. , 2000, Spine.

[36]  P. Roughley,et al.  Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. , 1999, The Biochemical journal.

[37]  R. Wynn,et al.  Cloning and Characterization of ADAMTS11, an Aggrecanase from the ADAMTS Family* , 1999, The Journal of Biological Chemistry.

[38]  K. Tanzawa,et al.  Identification of aggrecanase activity in medium of cartilage culture. , 1999, Journal of biochemistry.

[39]  R. Wynn,et al.  Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. , 1999, Science.

[40]  D. Buttle,et al.  The use of cleavage site specific antibodies to delineate protein processing and breakdown pathways. , 1999, Molecular pathology : MP.

[41]  B. Caterson,et al.  Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. , 1998, Osteoarthritis and cartilage.

[42]  P. Roughley,et al.  Aggrecan degradation in human intervertebral disc and articular cartilage. , 1997, The Biochemical journal.

[43]  S. Hukuda,et al.  Immunohistochemical Study of Matrix Metalloproteinase‐3 and Tissue Inhibitor of Metalloproteinase‐1 in Human Intervertebral Discs , 1996, Spine.

[44]  P. Roughley,et al.  Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. , 1995, The Biochemical journal.

[45]  C. Handley,et al.  [4] Assay of proteoglycan degradation , 1995 .

[46]  C. Handley,et al.  Assay of proteoglycan degradation. , 1995, Methods in enzymology.

[47]  L. Lohmander,et al.  The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. , 1993, Arthritis and rheumatism.

[48]  L. Lohmander,et al.  The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. , 1992, The Journal of clinical investigation.

[49]  Pearce Rh,et al.  Target tissue models: the proteoglycans and degeneration of the human intervertebral disc. , 1983 .

[50]  R. Pearce,et al.  Target tissue models: the proteoglycans and degeneration of the human intervertebral disc. , 1983, The Journal of rheumatology. Supplement.